共 136 条
[1]
Gilhus NE(2016)Myasthenia Gravis N Engl J Med 375 2570-2581
[2]
Rodolico C(2021)Benefit and danger from immunotherapy in myasthenia gravis Neurol Sci 42 1367-1375
[3]
Nicocia G(2021)International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update Neurology 96 114-122
[4]
Damato V(2018)When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies Ther Adv Neurol Disord 11 1756285617749134-131
[5]
Antonini G(2022)Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome Ann Clin Transl Neurol 9 122-1036
[6]
Liguori R(2015)Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies Lancet Neurol 14 1023-1077
[7]
Evoli A(2017)Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review Neurology 89 1069-358
[8]
Narayanaswami P(2018)Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review Muscle Nerve 58 344-2285
[9]
Sanders DB(2020)Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study Eur J Neurol 27 2277-395
[10]
Wolfe G(2020)Rituximab in AChR subtype of myasthenia gravis: systematic review J Neurol Neurosurg Psychiatry 91 392-e389